Albumin
Human serum albumin — the workhorse of intensive care, used in shock, burns, hepatic failure, and surgery.
BioPlasma Pharmaceutical Sp. z o.o. develops and manufactures albumin, human immunoglobulin, and blood clotting factors — first-line products for intensive care and national biosecurity.
Our mission is to secure Poland's independent supply of the most critical plasma-derived medicines — the ones hospitals cannot substitute in surgery, trauma, immunodeficiency, and infectious disease.
The production of immunoglobulins, albumin, dried plasma, and blood clotting factors within the country is of strategic importance. These preparations play a key role in crisis situations — martial law, disasters, and epidemics. A country that has a plant producing these unique preparations is protected from crises that may result in an inability to purchase drugs from abroad.
Applied R&D in plasma fractionation and pharmaceutical chemistry.
Manufacturing plasma-derived products at commercial scale under GMP.
Bringing strategically important, first-line medicines to Poland and export markets.
"Sovereign production of plasma-derived medicines is not an economic choice — it is a matter of public health resilience."
— Company thesisStrategically important medications used in intensive care units and for the treatment of severe diseases.
Human serum albumin — the workhorse of intensive care, used in shock, burns, hepatic failure, and surgery.
Polyvalent IgG for intravenous use — treatment of primary and secondary immunodeficiencies and autoimmune disease.
Lyophilized powder, 250 / 500 / 1000 IU glass vials.
Lyophilized powder, 250 / 500 / 1000 IU glass vials.
PCC — lyophilized powder in 500 IU glass vials for urgent reversal of anticoagulation.
Fibrinogen — 0.5 g or 1.0 g lyophilized powder per vial, essential in massive haemorrhage protocols. Fibrinogen + Fibrin complex on the surface of collagen sponge — analogous to TachoSil / Tachocomb, used as a haemostatic patch in complex surgery.
Purpose-built infrastructure for the isolation, purification, and finishing of plasma-derived biopharmaceuticals — engineered to GMP standards.
Cold-chain plasma logistics tied to certified collection centres.
Cohn-based ethanol fractionation of plasma into albumin, immunoglobulin and factor pastes.
Chromatography, viral inactivation, and formulation for pharmaceutical use.
Fill-finish of liquid and lyophilized products in glass vials under aseptic conditions.
Four core products anchor the industrial processing of normal donor plasma:
Polyvalent IgG for intravenous use — treatment of immunodeficiencies and autoimmune disease.
Human serum albumin — volume replacement in shock, burns, hepatic failure, and surgery.
Essential for haemophilia A treatment and management of bleeding disorders.
Critical for haemophilia B patients and complex coagulopathy management.
A senior team combining biotechnology, pharmaceutical regulation, clinical medicine and finance.
MSc, Doctor of Biochemistry
Automatic Control & Telemechanics
Medical Academy of Gdańsk
Medical Academy of Gdańsk · Professor at Cambridge
For partnership, supply, regulatory or investment enquiries, please reach out to our office. We respond to serious enquiries from healthcare authorities, hospitals, distributors and institutional investors.
Write to us biuro@axilon.pl